Expression of Tumor Necrosis Factor Receptor-associated Factor 6 in Lung Cancer Tissues |
Zhang, Xiu-Ling
(Department of Pathology, First Affiliated Hospital, Guangxi Medical University)
Dang, Yi-Wu (Department of Pathology, First Affiliated Hospital, Guangxi Medical University) Li, Ping (Department of Pathology, First Affiliated Hospital, Guangxi Medical University) Rong, Min-Hua (Research Department, Affiliated Cancer Hospital, Guangxi Medical University) Hou, Xin-Xi (Department of Pathology, First Affiliated Hospital, Guangxi Medical University) Luo, Dian-Zhong (Department of Pathology, First Affiliated Hospital, Guangxi Medical University) Chen, Gang (Department of Pathology, First Affiliated Hospital, Guangxi Medical University) |
1 | Beroukhim R, Mermel CH, Porter D, et al (2010). The landscape of somatic copy-number alteration across human cancers. Nature, 463, 899-905. DOI ScienceOn |
2 | Brothers JF, Hijazi K, Mascaux C, et al (2013). Bridging the clinical gaps: genetic, epigenetic and transcriptomic biomarkers for the early detection of lung cancer in the post-National Lung Screening Trial era. BMC Med, 11, 168. DOI |
3 | Chaudhry SI, Hooper S, Nye E, et al (2013). Autocrine IL-1beta-TRAF6 signalling promotes squamous cell carcinoma invasion through paracrine TNFalpha signalling to carcinoma-associated fibroblasts. Oncogene, 32, 747-58. DOI |
4 | Chen G, Kronenberger P, Teugels E, et al (2012). Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab. BMC Med, 10, 28. DOI ScienceOn |
5 | Chen G, Kronenberger P, Teugels E, et al (2013a). Effect of siRNAs targeting the EGFR T790M mutation in a non-small cell lung cancer cell line resistant to EGFR tyrosine kinase inhibitors and combination with various agents. Biochem Biophys Res Commun, 431, 623-9. DOI ScienceOn |
6 | Chen G, Noor A, Kronenberger P, et al (2013b). Synergistic effect of afatinib with su11274 in non-small cell lung cancer cells resistant to gefitinib or erlotinib. PLoS One, 8, 59708. DOI |
7 | Chen G, Umelo IA, Lv S, et al (2013c). miR-146a inhibits cell growth, cell migration and induces apoptosis in non-small cell lung cancer cells. PLoS One, 8, 60317. DOI |
8 | Chen W, Zheng R, Zhang S, et al (2014). Annual report on status of cancer in China, 2010. Chin J Cancer Res, 26, 48-58. |
9 | Elmetwali T, Young LS, Palmer DH (2010). CD40 ligand-induced carcinoma cell death: a balance between activation of TNFR-associated factor (TRAF) 3-dependent death signals and suppression of TRAF6-dependent survival signals. J Immunol, 184, 1111-20. DOI |
10 | Gazala S, Pelletier JS, Storie D, et al (2013). A systematic review and meta-analysis to assess patient-reported outcomes after lung cancer surgery. Scientific World J, 2013, 789625. |
11 | Granger CL, McDonald CF, Parry SM, et al (2013). Functional capacity, physical activity and muscle strength assessment of individuals with non-small cell lung cancer: a systematic review of instruments and their measurement properties. BMC Cancer, 13, 135. DOI |
12 | Guo LJ, Liao L, Yang L, et al (2014). MiR-125a TNF receptor-associated factor 6 to inhibit osteoclastogenesis. Exp Cell Res, 321, 142-52. DOI |
13 | Hirose T, Murata Y, Oki Y, et al (2012). Relationship of circulating tumor cells to the effectiveness of cytotoxic chemotherapy in patients with metastatic non-small-cell lung cancer. Oncol Res, 20, 131-7. DOI |
14 | Ishida T, Mizushima S, Azuma S, et al (1996). Identification of TRAF6, a novel tumor necrosis factor receptor-associated factor protein that mediates signaling from an amino-terminal domain of the CD40 cytoplasmic region. J Biol Chem, 271: 28745-8. DOI |
15 | Jundi M, Nadiri A, Al-Zoobi L, et al (2012). CD40-mediated cell death requires TRAF6 recruitment. Immunobiology, 217, 375-83. DOI |
16 | Liu H, Zhang T, Ye J, et al (2012). TNF receptor-associated factor 6 in advanced non-small cell lung cancer: clinical and prognostic implications. J Cancer Res Clin Oncol, 138, 1853-63. DOI |
17 | Kim JL, Cho KH, Park EC, Cho WH (2014). A single measure of cancer burden combining incidence with mortality rates for worldwide application. Asian Pac J Cancer Prev, 15 433-9. DOI ScienceOn |
18 | Kobayashi T, Walsh PT, Walsh MC, et al (2003). TRAF6 is a critical factor for dendritic cell maturation and development. Immunity, 19, 353-63. DOI |
19 | Lee NK, Lee SY (2002). Modulation of life and death by the tumor necrosis factor receptor-associated factors (TRAFs). J Biochem Mol Biol, 35, 61-6. DOI |
20 | Meng Q, Zheng M, Liu H, et al (2012). TRAF6 regulates proliferation, apoptosis, and invasion of osteosarcoma cell. Mol Cell Biochem, 371: 177-186. DOI |
21 | Ramshankar V, Krishnamurthy A (2013). Lung cancer detection by screening - presenting circulating miRNAs as a promising next generation biomarker breakthrough. Asian Pac J Cancer Prev, 14, 2167-2172. DOI ScienceOn |
22 | Siegel R, Ma J, Zou Z, Jemal A (2014). Cancer statistics, 2014. CA Cancer J Clin, 64, 9-29. DOI |
23 | Starczynowski DT, Lockwood WW, Delehouzee S, et al (2011). TRAF6 is an amplified oncogene bridging the RAS and NF-kappaB pathways in human lung cancer. J Clin Invest, 121, 4095-105. DOI |
24 | Sun H, Li X, Fan L, et al (2014). TRAF6 is upregulated in colon cancer and promotes proliferation of colon cancer cells. Int J Biochem Cell Biol, 53, 195-201. DOI |
25 | Xiao N, Li H, Luo J, et al (2012). Ubiquitin-specific protease 4 (USP4) targets TRAF2 and TRAF6 for deubiquitination and inhibits TNFalpha-induced cancer cell migration. Biochem J, 441, 979-86. DOI |
26 | Uribe P, Gonzalez S (2011). Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy. Pathol Res Pract, 207, 337-342. DOI |
27 | Wang R, Wang G, Zhang N, et al (2013). Clinical evaluation and cost-effectiveness analysis of serum tumor markers in lung cancer. Biomed Res Int, 2013, 195692. |
28 | Wang X, Ha T, Zou J, et al (2014). MicroRNA-125b protects against myocardial ischaemia/reperfusion injury via targeting p53-mediated apoptotic signalling and TRAF6. Cardiovasc Res, 102, 385-95. DOI |
29 | Zapata JM, Krajewska M, Krajewski S, et al (2000). TNFR-associated factor family protein expression in normal tissues and lymphoid malignancies. J Immunol, 165, 5084-96. DOI |
30 | Zhong L, Cao F, You Q (2013). Effect of TRAF6 on the biological behavior of human lung adenocarcinoma cell. Tumour Biol, 34, 231-9. DOI |